The Pharma Data

DECEMBER 16, 2020

Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. About Novavax.

Vaccine 52

Vaccine Government Immune Response Clinical Trials 52

Codon

OCTOBER 27, 2024

million people with TB went undetected in 2019, but these estimates are uncertain due to inaccuracies in testing. In 2019, physicians were unable to tailor effective antibiotic regimens for 39 percent of new TB cases because the assessments they relied on could not gauge which antibiotics the strains would be susceptible to.

Immune Response 77

Immune Response Doctors Disease Laboratories 77

The Pharma Data

SEPTEMBER 25, 2020

The data demonstrate that a single dose of JNJ-78436735 induced a strong neutralizing antibody response in nearly all participants aged 18 years and older and was generally well-tolerated. Immune responses were similar across the age groups studied, including older adults. Immune Response Data.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

Drug Target Review

JANUARY 3, 2024

These variants evade the immune response that the body has developed previously, which makes finding effective preventative and therapeutic approaches to control this disease difficult. 2019 November 4 [2023 December 18]; 34:11-26. Dr Salmen is now a postdoctoral fellow at the University of Michigan. 4 norovirus.

Virus 64

Virus Immune Response Vaccine Disease 64

The Pharma Data

FEBRUARY 22, 2021

New Phase 2 study assesses potential for refined antigen formulation to achieve optimal immune response, including in older adults. GSK’s response to COVID-19 has been one of the broadest in the industry, with two potential treatments in addition to our vaccine candidates in development. GSK commitment to tackling COVID-19.

Vaccine 52

Vaccine Immune Response Trials Clinical Trials 52

Drug Target Review

JUNE 9, 2023

This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, unveils some ground-breaking research on T- cell therapy for cancer , which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.

Treatment 105

Treatment Packaging Clinical Research Therapies 105

The Pharma Data

JUNE 2, 2022

” In the adult phase I/II clinical trials, AFX3772 was well tolerated in participants and demonstrated good immune responses compared to the current standard of care. In July 2021, the US Food and Drug Administration granted Breakthrough Therapy designation for AFX3772 to prevent S. About MAPSTM technology platform.

Vaccine 52

Vaccine Immune Response Clinical Trials Disease 52

The Pharma Data

MAY 31, 2022

In the adult phase I/II clinical trials, AFX3772 was well tolerated in participants and demonstrated good immune responses compared to the current standard of care. In July 2021, the US Food and Drug Administration granted Breakthrough Therapy designation for AFX3772 to prevent S. MAPS TM technology platform.

Vaccine 52

Vaccine Immune Response Clinical Trials Disease 52

Drug Target Review

OCTOBER 26, 2023

9 In addition, host immune responses further add to the complexity of developing cell-specific AAV capsids for clinical applications. It has been well established that exposure to wild-type AAV results in priming of the immune system against the virus. Nature reviews Drug discovery 18 , 358-378 (2019). Nyberg WA, et al.

Engineering 105

Engineering Virus Therapies Immune Response 105

Drug Target Review

NOVEMBER 17, 2023

NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).

Therapies 118

Therapies Cell Biology Clinical Trials Trials 118

The Pharma Data

SEPTEMBER 3, 2020

The data, published today in Nature Medicine , demonstrated that the Company’s investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited an immune response as demonstrated by “neutralizing antibodies” and prevented severe clinical disease – including weight loss, pneumonia and mortality – in Syrian golden hamsters upon challenge.

Vaccine 52

Vaccine Disease Immune Response Pharmaceutical Companies 52

PLOS: DNA Science

MAY 16, 2024

” I’ve long thought that SARS-CoV-2, or an immediate viral predecessor, emerged years before 2019 – at least as far back as 2013. • identifies parts of the virus to target to provoke an immune response from a vaccine. • reveals viral vulnerability to inspire novel treatments.

Virus 98

Virus DNA RNA Science 98

The Pharma Data

MARCH 9, 2021

, preliminary evidence suggests that canakinumab inhibits pro-tumor inflammation (PTI) to 1) enhance anti-tumor immune response; 2) reduce tumor cell proliferation, survival and invasiveness; and 3) impair angiogenesis 8. Canakinumab is a first-in-class interleukin-1beta (IL-1?)

Treatment 52

Treatment Immune Response Trials Clinical Trials 52

Drug Target Review

APRIL 26, 2023

In 2019, they successfully created nanoparticles made of polymers that could deliver mRNA encoding a bioluminescent protein to lung cells. In contrast, a modified adenovirus approach is very effective at delivering RNA but induces an immune response in the host, which limits its repeated use.

RNA 98

RNA Medical Schools Engineering DNA 98

The Pharma Data

JULY 6, 2021

In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. In addition, we observe a persistent and particularly robust, durable cellular immune response,” said Mathai Mammen, M.D., 2) variants during the study period.

Vaccine 52

Vaccine Immune Response Clinical Trials Disease 52

The Pharma Data

JANUARY 11, 2021

The advancing rollout of currently approved coronavirus disease 2019 (COVID-19) vaccines provides hope to many that existing lockdowns and social restrictions will soon be lifted, but experts suggest a “return to normal” likely won’t occur until herd immunity is achieved. The plan is to produce 2 billion doses this year. .

Vaccine 52

Vaccine Clinical Trials Immune Response Trials 52

The Pharma Data

NOVEMBER 19, 2020

The findings were that the death rate in several demographics exceeded the same period in 2019. The 2019 full data is not yet publicly available, but they calculated the 2019 death estimates using 2018 CDC data and 2019 population estimates from the U.S. The data was from the U.S. Source link.

Research 52

Research Nurses Disease Immune Response 52

The Pharma Data

NOVEMBER 9, 2020

NVX-CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains Novavax’ patented saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

Vaccine 52

Vaccine FDA Clinical Trials Immune Response 52

The Pharma Data

JANUARY 6, 2021

The alliance, announced on October 14, 2019 , has assisted in advancing the 89Zr CD8 Immuno-PET technology. CD8 T cells are the main effector cells involved in the immune response against tumor cells induced by immunotherapies and they also play a key role in multiple autoimmune diseases.

Licensing 52

Licensing Licensing Clinical Trials Pharmaceutical Companies 52

The Pharma Data

OCTOBER 26, 2020

The corticosteroid then works to relieve swelling, redness and itching by targeting the immune response that drives dry eye disease flares. . in January 2019 and is similar to EYSUVIS except at a higher 1% concentration of LE for post-surgery, versus.25% INVELTYS launched in the U.S. 25% for dry eye disease treatment.

Disease 52

Disease Treatment FDA FDA Approval 52

The Pharma Data

AUGUST 6, 2020

Early clinical results showed AstraZeneca’s candidate, AZD1222, triggered both antibody and T-cell immune responses. Clover Biopharmaceuticals has an S-Trimer subunit vaccine candidate, SCB-2019 , which is being evaluated with two adjuvant systems by GlaxoSmithKline and Dynavax in phase 1 study, with results expected this month.

Vaccine 52

Vaccine Licensing Licensing Immune Response 52

The Pharma Data

DECEMBER 23, 2020

All 38 subjects who were evaluable for immunogenicity had balanced cellular and humoral immune responses following the second dose of INO-4800. The antigen is processed naturally in the cell and triggers the desired T cell and antibody-mediated immune responses. About INOVIO.

DNA 40

DNA Vaccine Clinical Trials Immune Response 40

The Pharma Data

NOVEMBER 12, 2020

The CALAVI trials were launched based on preclinical and early clinical evidence that Calquence could decrease the hyperinflammatory immune response and improve clinical outcomes in patients hospitalised with respiratory symptoms of COVID-19.1 Wilmington, DE; AstraZeneca Pharmaceuticals LP; 2019. Available online.

Trials 52

Trials Clinical Trials Immune Response FDA Approval 52

The Pharma Data

MARCH 8, 2021

, preliminary evidence suggests that canakinumab inhibits pro-tumor inflammation (PTI) to 1) enhance anti-tumor immune response; 2) reduce tumor cell proliferation, survival and invasiveness; and 3) impair angiogenesis 8. Canakinumab is a first-in-class interleukin-1beta (IL-1?)

Immune Response 52

Immune Response Clinical Trials Trials Treatment 52

The Pharma Data

NOVEMBER 30, 2020

NVX-CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein adjuvanted with Novavax’ patented saponin-based Matrix-M to enhance the immune response and stimulate high levels of neutralizing antibodies.

Clinical Development 52

Clinical Development Vaccine Clinical Trials Immune Response 52

PLOS: DNA Science

OCTOBER 19, 2023

The disease may develop in response to an environmental factor, such as repeated head injuries. One widely-quoted study that investigated nearly 20,000 professional football players who had participated in at least one game between 1960 and 2019 revealed a four-fold elevated risk of developing ALS compared to the general population.

Therapies 111

Therapies FDA Clinical Trials DNA 111

Drug Target Review

FEBRUARY 28, 2024

Crain’s New York Business recognised Kate as one of the top women in tech in 2019. gammadelta T cells link innate and adaptive immune responses. She helped lead Curadigm’s spin-out from Nanobiotix and developed collaborations and partnerships around a novel platform to increase therapeutic bioavailability. Kalyan S, Kabelitz D.

Therapies 105

Therapies Engineering Molecular Biology Science 105

The Pharma Data

OCTOBER 22, 2020

The higher incidence of global WPV1 cases seen during 2020 continues, with 121 cases reported between 1 January – 5 October 2020 compared to 85 for the same period in 2019, a 42% increase. The number of cases in 2020 is 409 as at 5 October 2020, already exceeding the 378 cases reported for the whole of 2019. Wild poliovirus. .

Vaccine 52

Vaccine International Immune Response Virus 52

The Pharma Data

OCTOBER 26, 2020

based company said the preventative medication boosts immune responses in older and younger adults against the novel coronavirus. Moderna has fully enrolled its late-stage coronavirus disease 2019 (COVID-19) vaccine trial by hitting its target of 30,000 participants. The approval marks the first drug approved by the U.S.

Vaccine 52

Vaccine FDA Approval FDA Clinical Trials 52

The Pharma Data

OCTOBER 9, 2021

Due to the innovative design of deucravacitinib, Bristol Myers Squibb earned recognition with the 2019 Thomas Alva Edison Patent Award for the science underpinning the clinical development of deucravacitinib. At therapeutic doses, deucravacitinib does not inhibit JAK1, JAK2 or JAK3. Deucravacitinib is not approved for use in any country.

Trials 52

Trials Disease Science Immune Response 52

The Pharma Data

FEBRUARY 24, 2022

The Committee considered that the available evidence was sufficient to conclude that the immune response to a booster dose in adolescents would be at least equal to that in adults. No new safety concerns were identified from the data available.

Vaccine 52

Vaccine FDA Small Molecule Immune Response 52

The Pharma Data

JANUARY 31, 2021

Clover’s S-Trimer antigen adjuvanted with CpG 1018 plus alum demonstrated low reactogenicity while providing high levels of neutralizing antibodies and a strong Th1-biased cell-mediated immune response. Dynavax developed CpG 1018 to provide an increased vaccine immune response, which has been demonstrated in HEPLISAV-B.

Vaccine 52

Vaccine Trials Virus RNA 52

The Pharma Data

NOVEMBER 10, 2020

Oral administration of anti-CD3 monoclonal antibody is a novel approach to induce an anti-inflammatory immune response to suppress inflammation by inducing T regulatory (Tregs) cells in animal studies 3 ,4. Crohn’s & Colitis 360, Volume 1, Issue 2, July 2019, otz009. Weiner, H. Korzenik, J. and Snapper, S.

Clinical Trials 40

Clinical Trials Science Disease Trials 40

The Pharma Data

NOVEMBER 14, 2020

The interim analysis showed that a single dose of the COVID-19 vaccine candidate induced a robust immune response and was generally well-tolerated. PHASE 3 ENSEMBLE 2 STUDY.

Clinical Trials 40

Clinical Trials Vaccine Trials Pharmaceutical Companies 40

The Pharma Data

SEPTEMBER 17, 2020

The Elecsys Anti-SARS-CoV-2 serology test can be used to quantitatively measure antibodies in people who have been exposed to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and can play an important part in characterising a vaccine-induced immune response. In 2019, Roche invested CHF 11.7

Vaccine 52

Vaccine Virus Clinical Trials Immune Response 52

The Pharma Data

SEPTEMBER 10, 2021

OS data cut-off date was 12 March 2021; PFS data cut-off date was 24 July 2019. Imfinzi (durvalumab) is a human monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80, countering the tumour’s immune-evading tactics and releasing the inhibition of immune responses.

Treatment 52

Treatment Immune Response Trials Clinical Trials 52

New Drug Approvals

DECEMBER 16, 2023

3 Additionally, iptacopan has the benefit of targeting factor B, which only affect the alternative complement pathway, leaving the classic and lectin pathway untouched for the body to still mount adequate immune responses against pathogens. April 2019). 1] It is a complement factor B inhibitor that was developed by Novartis. [1]

FDA 62

FDA Small Molecule FDA Approval Treatment 62